Lymphangioleiomyomatosis

Česká verzia

Authors: Martina. Doubková ¹; Marianna Štefániková ¹; Vladimír Čan ²; Zdeněk Merta ¹; Marek Svoboda ^3,4
Authors place of work: Klinika nemocí plicních a tuberkulózy LF MU a FN Brno ¹; Chirurgická klinika LF MU a FN Brno ²; Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno ³; Oddělení epidemiologie a genetiky nádorů, Masarykův onkologický ústav, Brno ⁴
Published in the journal: Klin Onkol 2019; 32(5): 367-374
Category: Original Articles
doi: https://doi.org/10.14735/amko2019367

Summary

Background: Lymphangioleiomyomatosis (LAM) is a rare systemic disease that occurs sporadically (S/LAM) or as part of tuberous sclerosis (TS/LAM). LAM is characterized by proliferation of abnormal smooth muscle cells. This disease clinically manifests as dyspnea on exertion and pneumothorax. Lymphadenopathy in the abdominal and pelvic region leading to lymphatic obstruction can also occur. LAM is associated with kidney angiomyolipoma and meningioma. The disease is diagnosed histologically and/or using typical high-resolution computed tomography findings and anamnestic information. In histopathological studies, the diagnosis is supported by detection of characteristic LAM cells. Mammalian target of rapamycin (mTOR) inhibitors are possible treatment options.

Material and methods: Ten consecutive patients diagnosed with LAM and pulmonary manifestation (eight with S/LAM and two with TS/LAM) in 2002–2018 were retrospectively analyzed. Their individual clinical characteristics and our treatment experience are described.

Results: The patients varied in terms of disease stage. The best predictors of prognosis were lung function parameters (forced vital capacity, forced expiratory volume in 1 second, and diffusing capacity for carbon monoxide). Four patients are currently being treated with mTOR inhibitors. This treatment stabilized lung functions in all four patients. The median follow-up was 48 months (12–132 months). Median survival was not achieved and only three patients died.

Conclusion: An interdisciplinary approach is required to care for LAM patients. Cooperation of pneumologists, surgeons, oncologists, and geneticists is needed. Treatment with mTOR inhibitors led to stabilization in our patients. The side effects were well managed.

Keywords:

sirolimus – lymphangioleiomyomatosis – rapamycin

Zdroje

1. Lauterbacher R. Dysembriomes metotypiques des reins carcinnose submiliere aique poumon avec emphysemae generalise et double pneumothorax. Ann Med Interne (Paris) 1918; 5: 435–450.

2. Van Stössel E. Uber muskuläre Cirrhose der Lunge. Beitr Klin Tuberk 1937; 90: 432–442.

3. Laipply TC, Sherrick JC. Intrathoracic angiomyomatous hyperplasia associated with chronic chylothorax. Lab Incest 1958; 7 (4): 387–400.

4. Miřejovský P, Kulhánková J. Plicní lymfangioleiomyomatóza. Česk Patol 1980; 16 (3): 132–138.

5. Halíková J, Miřejovský P, Fučík J et al. Plicní lymfangioleiomyomatóza. Stud Pneumol Phtiseol Cechoslov 1990; 50 (4): 239–243.

6. Johnson SR, Cordier JF, Lazor R et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35 (1): 14–26. doi: 10.1183/09031936.00076209.

7. Taveira-DaSilva AM, Moss J. Epidemiology, pathogenesis and diagnosis of lymphangioleiomyomatosis. Expert Opin Ophran Drugs 2016; 4 (4): 369–378. doi: 10.1517/21678707.2016.1148597.

8. Ryu JH, Moss J, Beck GJ et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173 (1): 105–111. doi: 10.1164/rccm.200409-1298OC.

9. Smolarek TA, Wessner LL, McCormack FX et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations, chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998; 62 (4): 810–815. doi: 10.1086/301804.

10. Carsillo T, Astrinidis A, Henske EP. Mutation in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000; 97 (11): 6085–6090. doi: 10.1073/pnas.97.11.6085.

11. Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 2001; 164 (8Pt1): 1537–1540. doi: 10.1164/ajrccm.164.8.2104095.

12. Colley MH, Geppert E, Franklin WA. Immunohistochemical detection of steroid receptors in case of pulmonary lymphangioleiomyomatosis. Am J Surg Pathol 1989; 13 (9): 803–807. doi: 10.1097/00000478-198909000-00011.

13. Matsui K, Takeda K, Yu ZX et al. Down regulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymmphangioleiomyomatosis following therapy: an immunohistochemical study. Am J Respir Crit Care Med 2000; 161 (3Pt1): 1002–1009. doi: 10.1164/ajrccm.161.3.9904009.

14. Oberstein EM, Fleming LE, Gomez-Marin O et al. Pulmonary lymphangioleiomyomatosis (LAM): examining oral contraceptive pills and the onset of disease. J Women Health 2003; 12 (1): 81–85. doi: 10.1089/154099903 321154176.

15. Silerstein EF, Ellis K, Wolff M et al. Pulmonary lymphangioleiomyomatosis. Am J Roentgenol 1974; 120 (4): 832–850.

16. Doubková M, Turčáni P, Pokojová E et al. Lymfangioleiomyomatóza (kazuistika a přehled případů popsaných v české a slovenské lékařské literatuře). Stud Pneumol Phtiseol 2005; 656 (4): 154–159.

17. Svatoň M, Pešek M, Ferda J. Lymfangioleiomyomatóza – cesta do nitra buněk. Kazuistiky v alergologii, pneumologii a ORL 2013; 10 (3): 3–8.

18. Homolka J, Svobodová L, Slováková A. Lymfangioleiomyomatóza u postmenopauzální ženy. Cas Lek Cesk 2003; 142 (2): 117–119.

19. Aubry MC, Myers JL, Ryu JH et al. Pulmonary lymphangioleiomyomatosis in a man. Am J Respir Crit Care Med 2000 (2Pt1); 162: 749–752. doi: 10.1164/ajrccm. 162.2.9911006.

20. Urban T, Lazor R, Lancronique J et al. Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM“O”P). Medicine (Baltimore) 1999; 78 (5): 321–337. doi: 10.1097/00005792-199909000-00004.

21. Harknett EC, Chang WY, Byrnes S et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM 2011; 104 (11): 971–979. doi: 10.1093/qjmed/hcr116.

22. Oprescu N, McCormack FX, Byrnes S et al. Clinical predictors of mortality and cause of death in lymphangioleilomyomatosis: a population-based registry. Lung 2013; 191 (1): 35–42. doi: 10.1007/s00408-012-9419-3.

23. Wataya-Kaneda M, Tanaka M, Hamasaki T et al. Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 1666 Japanese patients. PLoS One 2013; 8 (5): e63910. doi: 10.1371/journal.pone.0063910.

24. Cudzilo CJ, Szczesniak RD, Brody AS et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 2013; 144 (2): 578–585. doi: 10.1378/chest.12-2813.

25. McCormack FX, Gupta N, Finlay GR et al. Official American Thoracic Society/Japanese Respiratory Society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med 2016; 194 (6): 748–761. doi: 10.1164/rccm.201607-1384ST.

26. Gupta N, Vassallo R, Wikenheiser-Brokamp KA et al. Diffuse cystic lung disease: part I. Am J Respir Crit Care Med 2015; 191 (12): 1354–1366. doi: 10.1164/rccm.201411-2094CI.

27. Matsui K, Tatsuguchi A, Valencia J et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000; 31 (10): 1242–1248. doi: 10.1053/hupa.2000.18500.

28. Avilla NA, Kelly J, Chu S et al. Lymphangioleiomyomatosis: abdominopelvic CT and US findigs. Radiology 2000; 216 (1): 147–153. doi: 10.1148/radiology.216.1.r00jl42147.

29. Glasgow CG, Avila NA, Lin JP et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other disease. Chest 2009; 135 (5): 1293–1300. doi: 10.1378/chest.08-1160.

30. Young L, Lee HS, Inoue Y et al. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013; 1 (6): 445–452. doi: 10.1016/S2213-2600 (13) 70090-0.

31. Grzegorek I, Lenze D, Chabowski M et al. Immunohistochemical evaluation of pulmonary lymphangioleiomyomatosis. Anticancer Res 2015; 35 (6): 3353–3360.

32. Pacheco-Rodriguez G, Kumaki F et al. Chemokine-enhanced chemotaxis of lymphangioleiomymatosis cells with mutation in the tumor suppressor TSC2 gene. J Immunol 2009; 182 (3): 1270–1277. doi: 10.4049/jimmunol.182.3.1270.

33. Pacheco-Rodriguez G, Steagall WK et al. TSC2 los in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res 2007; 67 (21): 10573–10581. doi: 10.1158/0008-5472.CAN-07-1356.

34. Gupta N, Finlay GA, Kotloff RM et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society/Japanese Respiratory Society clinical practice guideline. Am J Respir Crit Care Med 2017; 196 (10): 1337–1348. doi: 10.1164/rccm.201709-1965ST.

35. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160 (2): 628–633. doi: 10.1164/ajrccm.160.2.9901027.

36. Sandrini A, Silverstone E, Yates DH. Menstrual cycle variation of retroperitoneal lymphangioleiomyomas in lymphangioleiomyomatosis. Intern Med J 2011; 41 (12): 832–835. doi: 10.1111/j.1445-5994.2011.02593.x.

37. Yockey CC, Riepe RE, Ryan K. Pulmonary lymphangioleiomyomatosis complicated by pregnancy. Kans Med 1986; 87 (10): 277–278, 293.

38. Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax 2002; 57 (12): 1085–1086. doi: 10.1136/thorax.57.12.1085.

39. Shen A, Iseman MD, Waldron JA et al. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest 1987; 91 (5): 782–785. doi: 10.1378/chest.91.5.782.

40. Taveira-Da Silva AM, Stylianou MP, Hedin CJ et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126 (6): 1867–1874. doi: 10.1378/chest.126.6.1867.

41. Banner AS, Carrington CB, Emory WB et al. Efficacy of oophorectomy in lymphangioleiomyomatosis and benign metastasizin leiomyoma. N Engl J Med 1981; 305 (4): 204–209. doi: 10.1056/NEJM198107233050406.

42. Harari S, Cassandro R, Chiodini I et al. Effect of a gonadotrophin-releasing homrone analogue on lung function in lymphangioleiomyomatosis. Chest 2008; 133 (2): 448–454. doi: 10.1378/chest.07-2277.

43. McCormack FX, Inoue Y, Moss J et al. National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011 (17); 364: 1595–1606. doi: 10.1056/NEJMoa1100391.

44. Gao N, Zhang T, Ji J et al. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis. Orphanet J Rare Dis 2018; 13 (1): 134. doi: 10.1186/s13023-018-0874-7.

45. Bendeck MP, Conte M, Zhang M et al. Doxycycline modulates smooth muscle cell grouwth, migration, and matrix remodeling after arterial injury. Am J Pathol 2002; 160 (3): 1089–1095. doi: 10.1016/S0002-9440 (10) 64929-2.

46. Chang WY, Cane JL, Kumaran M et al. A 2-year randomised placebo-controlled trial of doxycykline for lymphangioleiomyomatosis. Eur Respir J 2014; 43 (4): 1114–1123. doi: 10.1183/09031936.00167413.

47. Čan V, Doubková M, Hanke I, Penka I. Lymfangioleiomyomatóza z pohledu chirurga. Kazuistiky v alergologii, pneumologii a ORL 2016; 13 (2): 10–15.

48. Bittmann I, Dose TB, Muller C et al. Lymphangioleiomyomatosis: recurrence after single-lung transplantation. Hum Pathol 1997; 26 (12): 1420–1423. doi: 10.1016/s0046-8177 (97) 90233-1.

49. Zaki KS, Aryan Z, Mehta AC et al. Recurrence of lymphangioleiomyomatosis: nine years after a bilateral lung transplantacion. World J Transplant 2016; 6 (1): 249–254. doi: 10.5500/wjt.v6.i1.249.

50. Pechet TT, Meyers BF, Guthrie TJ et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplnat 2004; 23 (3): 301–308. doi: 10.1016/S1053-2498 (03) 00195-5.

51. Sakompani P, Kasemsam C, Yottasurodom C. Retransplantaton after single lung transplantation. Transplant Proc 2008; 40 (8): 2617–2619. doi: 10.1016/j.transproceed.2008.07.120.

52. Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol 2010; 8 (1): 9–19. doi: 10.1089/lrb.2009.0024.

53. Gupta N, Lee HS, Young LR et al. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur Respir J 2019; 53 (4): 1802066. doi: 10. 1183/13993003.02066-2018.

54. Hayashida M, Seyama K, Inoue Y et al. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology 2007; 12 (4): 523–530. doi: 10.1111/j.1440-1843.2007.01101.x.